(Q42757678)

6 November 2017

Study is needed of visual field defects associated with any long term antiepileptic drug (English)

1 reference

6 November 2017

Rao GP

1

1 reference

6 November 2017

Fat FA

2

1 reference

6 November 2017

Kyle G

3

1 reference

6 November 2017

Leach JP

4

1 reference

6 November 2017

Chadwick DW

5

1 reference

6 November 2017

Batterbury M

6

1 reference

6 November 2017

language of work or name

English

0 references

publication date

1 July 1998

1 reference

6 November 2017

1 reference

6 November 2017

317

1 reference

6 November 2017

7152

1 reference

6 November 2017

206

1 reference

Severe persistent visual field constriction associated with vigabatrin

6 November 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1113550

PubMed Central

reference URL

Severe persistent visual field constriction associated with vigabatrin. Asymptomatic as well as symptomatic defects occur with vigabatrin

27 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1113550

PubMed Central

reference URL

Severe persistent visual field constriction associated with vigabatrin. Benefit: risk ratio must be calculated for individual patients

16 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1113550

PubMed Central

reference URL

16 August 2018

Identifiers

DOI

10.1136/BMJ.317.7152.206

1 reference

6 November 2017

1 reference

6 November 2017

PubMed publication ID

9665915

1 reference